The worldwide nasal polyps treatment market is anticipated to increase over the forecast period as a result of the market participants’ clinical studies assessing the efficacy of novel medications for the treatment of nasal polyps. For instance, the Phase III research for Hoffmann-La Roche, a healthcare corporation, was finished on March 11, 2019. In adults with chronic rhinosinusitis and nasal polyps who had not responded well to traditional therapies, the trial evaluated the effectiveness and safety of omalizumab with a placebo. Members got subcutaneous injections of omalizumab in doses ranging from 75 mg to 600 mg once every 2 weeks or once every 4 weeks.
Over the course of the projection period, regulatory authorities’ recommendations for approval of a novel medicine used to treat nasal polyps are anticipated to propel market expansion. For instance, a pharmaceutical company called Novartis received a favourable opinion on June 26, 2020, proposing the approval of their medicine Xolair. For the treatment of people with severe chronic rhinosinusitis and nasal polyps, intranasal corticosteroids are used in conjunction with Xolair. The nasal polyps therapy Xolair targets and blocks immunoglobulin E (IgE), which aids in reducing the size of the polyps.
Request Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/2775
Over the projection period, the coronavirus disease (COVID-19) pandemic is anticipated to propel market growth for nasal polyps therapy. The most recent pandemic epidemic, COVID-19, was initially identified in Wuhan, China, on December 31, 2019. On March 11, 2020, COVID-19, a coronavirus illness, was classified as a pandemic by the World Health Organization. After July 27, 2022, fewer new cases are reported, according to the World Health Organization’s (WHO) Weekly Epidemiological Update on COVID-19. As a result, about 6.39 million fatalities and almost 572 million cases had been documented as of July 27, 2022.
The global market for nasal polyp treatment is anticipated to increase over the course of the forecast period as more regulatory bodies enlist in the development of novel medications for the treatment of nasal polyps. An example is the additional Biologics License Application for Fasenra (benralizumab) for patients with inadequately managed chronic rhinosinusitis with nasal polyps that was updated by the U.S. Food and Drug Administration (FDA) on March 14, 2022. In order to provide fasenra to patients with chronic rhinosinusitis and nasal polyps, the pharmaceutical and biotechnology firm AstraZeneca received a request from the U.S. FDA for further clinical data.
In order to discover novel medications for the treatment of nasal polyps, market participants are working together to perform clinical studies. Over the course of the forecast period, this is anticipated to fuel the expansion of the worldwide market for treating nasal polyps. For example, in July 2018, Safoni, a pharmaceutical and healthcare firm, and Regeneron Pharmaceuticals, a biotechnology company, successfully completed a phase III clinical research to assess the effectiveness of dupilumab compared to placebo in reducing nasal congestion severity and endoscopic nasal polyp score in people with bilateral nasal polyposis.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2775
Key Takeaways
The market for treating nasal polyps is anticipated to develop at a CAGR of 6.9% from 2022 to 2030 as a result of expansion in promising regions, particularly Europe. While the largest market share was in North America.
Over the forecast period, new regulatory rules for the development of novel medications for treatment are anticipated to propel market expansion. For instance, the Center for Drug Evaluation and Research provided guidelines to the pharmaceutical industry in December 2021 regarding the creation of new medications for treatment.
The recommendations aided major actors in the creation of pharmaceuticals or biological treatments for chronic rhinosinusitis with nasal polyps. The guidelines cover trial population, design, efficacy, statistical analysis, and safety for medications being developed for the treatment of chronic rhinosinusitis with nasal polyps, according to the US Food and Drug Administration (FDA).
Sanofi S.A., OptiNose Inc., Teva Pharmaceutical Industries Limited, Hoffmann-La Roche Ag, Taro Pharmaceuticals Industries Ltd., Fougera Pharmaceuticals Inc., Astrazeneca Plc, Novartis International Ag, Norton Waterford Ltd., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc, Dohme Corp., and Intersect Ent, are some of the major companies competing in the global nasal polyps treatment market.
tial, drivers, SWOT analysis, and Nasal Polyps Treatment development plans in coming years.
Reasons to buy this Nasal Polyps Treatment Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Nasal Polyps Treatment market size estimation and recent advancements in the industry are explained.
Buy this Complete Business Report @
https://www.coherentmarketinsights.com/insight/buy-now/2775
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
- Market Dynamics
- Global Nasal Polyps Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Research and Development
- Government Initiatives
- Global Nasal Polyps Treatment Market, By Drug Class, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Nasal corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Fluticasone
- Budesonide
- Mometasone
- Triamcinolone
- Others – Beclomethasone, Ciclesonide, etc.
- Oral/Injectable Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Prednisone
- Combination
- Nasal corticosteroids
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Interleukin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Dupilumab
- Others (IL 10, IL 25 etc.)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Mepolizumab
- Omalizumab
- Others
- Others (Aspirin, anticholinergic agent and etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- Global Nasal Polyps Treatment Market, By Route of Administration, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- Global Nasal Polyps Treatment Market, By Distribution Channel, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- Global Nasal Polyps Treatment Market, By Region, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2030
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Hoffmann-La Roche Ag
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Fougera Pharmaceuticals Inc.,
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis International Ag
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi S.A.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Intersect Ent
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Dohme Corp
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Norton Waterford Ltd
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astrazeneca Plc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Taro Pharmaceuticals Industries Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Industries Limited
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- OptiNose Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Analyst Views
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837